Core Laboratories (NYSE:CLB) Price Target Cut to $15.00 by Analysts at Stifel Nicolaus

Core Laboratories (NYSE:CLB) had its price target lowered by research analysts at Stifel Nicolaus from $19.00 to $15.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “hold” rating on the oil and gas company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 23.46% from the company’s current price.

Separately, Citigroup upgraded Core Laboratories from a “sell” rating to a “neutral” rating and increased their price target for the company from $15.00 to $16.00 in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $15.75.

Core Laboratories Price Performance

NYSE:CLB remained flat at $12.15 during trading hours on Tuesday. The company had a trading volume of 86,041 shares, compared to its average volume of 384,586. The firm has a market capitalization of $567.43 million, a P/E ratio of 18.35, a P/E/G ratio of 0.99 and a beta of 1.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.32 and a quick ratio of 1.71. The firm has a fifty day moving average of $14.91 and a 200 day moving average of $17.61. Core Laboratories has a 1-year low of $10.14 and a 1-year high of $25.13.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.23. Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. As a group, equities research analysts anticipate that Core Laboratories will post 0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Core Laboratories

Hedge funds and other institutional investors have recently bought and sold shares of the company. Assetmark Inc. acquired a new stake in Core Laboratories during the fourth quarter worth approximately $26,000. Smartleaf Asset Management LLC grew its stake in shares of Core Laboratories by 173.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company’s stock valued at $35,000 after buying an additional 1,293 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Core Laboratories by 2,688.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,426 shares of the oil and gas company’s stock worth $42,000 after purchasing an additional 2,339 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Core Laboratories by 843.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company’s stock valued at $57,000 after buying an additional 2,936 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Core Laboratories in the 4th quarter worth about $123,000. Institutional investors and hedge funds own 97.81% of the company’s stock.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.